中华医学会肺癌临床诊疗指南(2025版)
中华医学会组织呼吸、肿瘤、胸外科、放疗、影像和病理等领域专家制定肺癌临床诊疗指南2025版,较2024版在筛查、基因检测、靶向治疗和免疫治疗等方面作出更新,为各级医生提供循证推荐。
要点
- 新增不推荐进行肺癌筛查的人群,并强调高危人群筛查前应充分知情LDCT获益与风险。
- 更新早中期术后及晚期非小细胞肺癌(NSCLC)的基因检测推荐。
- 晚期EGFR突变、免疫新辅助、EGFR-TKI耐药及KRAS G12C等患者新增治疗选择。
核心结论
- 指南基于国家批准药物、国际指南和我国临床实践,整合最新循证证据,为各级医生提供全面的肺癌诊疗推荐。
研究设计与样本
- 中华医学会召集呼吸、肿瘤、胸外科、放疗、影像和病理等领域专家共同制定。
主要发现
- 筛查部分新增不推荐进行肺癌筛查的人群。
- 强调高危人群接受低剂量CT(LDCT)筛查前应充分知情获益与风险。
- 更新早中期术后及晚期NSCLC的基因检测推荐。
- 晚期EGFR突变患者除单药外,部分患者联合治疗可能带来更好疾病控制。
- 免疫新辅助治疗及EGFR-TKI耐药后新增更多获批治疗选择。
临床怎么用
- 临床医生可参照本指南进行肺癌筛查、基因检测、免疫分子标志物检测、治疗及随访。
- 对高危人群筛查前应充分告知LDCT筛查的潜在获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Zhonghua Zhong Liu Za Zhi. 2025 Sep 23;47(9):769-810. doi: 10.3760/cma.j.cn112152-20250511-00215. ABSTRACT To further standardize lung cancer prevention and treatment measures in China, enhance the quality of diagnosis and treatment, improve patient prognosis, and provide evidence-based medical guidance for clinicians at all levels, the Chinese Medical Association convened experts from respiratory medicine, oncology, thoracic surgery, radiotherapy, imaging, and pathology to develop the "Chinese Medical Association's clinical diagnosis and treatment guidelines for lung cancer (2025 edition)". This consensus resulted in several updates from the 2024 version. In the screening section, a new recommendation has been added to specify populations not advised to undergo lung cancer screening. It also emphasizes that individuals at high risk for lung cancer should be fully informed of the potential benefits and risks of low-dose CT (LDCT) screening before undergoing the examination. With the advancement of treatment options, updates have been made to the recommended genetic testing for patients with early- and mid-stage postoperative and advanced non-small cell lung cancer (NSCLC). For patients with advanced epidermal growth factor receptor (EGFR) mutations, in addition to a broader range of monotherapy options, the application of combination therapies may offer better disease control for certain patients. Furthermore, more treatment options have been approved for patients undergoing immunotherapy-based neoadjuvant treatment and for those who develop resistance to EGFR tyrosine kinase inhibitors (TKIs). For patients with previously limited treatment options, such as those with KRAS G12C mutations, HER-2 mutations, or small cell lung cancer after resistance development, the approval of novel drugs has brought significantly improved efficacy and prognosis. These recommendations are based on state-approved drug applications, international guidelines, and current clinical practices in China, integrating the latest evidence-based medical research in screening, diagnosis, pathology, genetic testing, immune molecular marker detection, treatment methods, and follow-up care. The goal is to provide comprehensive and reasonable recommendations for clinicians, imaging specialists, laboratory technicians, and other medical staff at all levels. PMID: 40796288 | DOI: 10.3760/cma.j.cn112152-20250511-00215
引用
- 指南共识 · 肺结节与肺癌筛查:Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。